Negro Roberto, Greco Eupremio Luigi, Greco Giacomo
Division of Endocrinology, "V. Fazzi" Hospital, Lecce, Italy.
San Raffaele Hospital, Faculty of Medicine, Milano, Italy.
Exp Clin Endocrinol Diabetes. 2019 Apr;127(4):215-219. doi: 10.1055/s-0043-122383. Epub 2018 Mar 20.
We investigated the effect of alogliptin and gliclazide on endothelial progenitor cells (EPCs) in type 2 diabetes.
Eighty patients with type 2 diabetes and HbA1c between 7.5% and 8.5% were randomized to receive either alogliptin (25 mg/daily) or gliclazide extended-release (30 mg/daily for HbA1c 7.5-8.0% and 60 mg/daily for HbA1c 8.0-8.5%) in combination with metformin for 4 months. At baseline and 4 months, clinical and laboratory parameters of EPCs were determined.
After 4 months of treatment, alogliptin and gliclazide resulted in a similar significant reduction in HbA1c (%) (8.0±0.3 vs. 7.1±0.2, and 8.0±0.3 vs. 7.0±0.2, respectively; P<0.05) and a similar and significant increase in EPC count (cells/10 WBC) (CD45CD133KDR : 2.2±1.2 vs. 3.7±1.6, CD45CD34KDR: 3.3±18 vs. 4.9±1.8; P<0.05 for alogliptin; CD45CD133KDR: 2.3±1.3 vs. 36±1.5, CD45CD34KDR: 3.1±1.3 vs. 46±1.7; P<0.05 for gliclazide).
Both alogliptin and gliclazide demonstrated a beneficial effect in increasing EPCs in poorly controlled type 2 diabetes. As alogliptin and gliclazide exhibit different mechanisms of action, the observed increase in EPCs seems to be due to their glucose-lowering effect.
我们研究了阿格列汀和格列齐特对2型糖尿病患者内皮祖细胞（EPCs）的影响。
80例2型糖尿病患者，糖化血红蛋白（HbA1c）在7.5%至8.5%之间，被随机分为接受阿格列汀（25毫克/每日）或格列齐特缓释片（HbA1c为7.5 - 8.0%时30毫克/每日，HbA1c为8.0 - 8.5%时60毫克/每日）联合二甲双胍治疗4个月。在基线和4个月时，测定EPCs的临床和实验室参数。
治疗4个月后，阿格列汀和格列齐特使HbA1c（%）均显著降低（分别为8.0±0.3对7.1±0.2，8.0±0.3对7.0±0.2；P<0.05），且EPC计数（细胞/10个白细胞）均显著增加（阿格列汀组：CD45CD133KDR：2.2±1.2对3.7±1.6，CD45CD34KDR：3.3±1.8对4.9±1.8；P<0.05；格列齐特组：CD45CD133KDR：2.3±1.3对3.6±1.5，CD45CD34KDR：3.1±1.3对4.6±1.7；P<0.05）。
阿格列汀和格列齐特在控制不佳的2型糖尿病患者中均显示出增加EPCs的有益作用。由于阿格列汀和格列齐特具有不同的作用机制，观察到的EPCs增加似乎归因于它们的降糖作用。
